US2023080536A1PendingUtilityA1

Alpha-synuclein protofibril-binding antibodies

54
Assignee: BIOARCTIC ABPriority: Jun 26, 2020Filed: Apr 21, 2022Published: Mar 16, 2023
Est. expiryJun 26, 2040(~13.9 yrs left)· nominal 20-yr term from priority
Inventors:Eva NordströmJessica SigvardsonPatrik Nygren
C07K 2317/92A61K 2039/505C07K 2317/76C07K 16/18A61P 25/00C07K 2317/90C07K 2317/24C07K 2317/33
54
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present disclosure is based, in part, on the discovery of antibodies that selectively targets human α-synuclein aggregates such as oligomers/protofibrils, such as BAN0805. BAN0805 has a lower tendency to bind to the undesired monomeric α-synuclein target as compared to mouse monoclonal antibody mAb47.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . An antibody comprising a heavy chain comprising the amino acid sequence of SEQ ID NO: 1 and a light chain comprising the amino acid sequence of SEQ ID NO: 2. 
     
     
         2 .- 25 . (canceled)

Join the waitlist — get patent alerts

Track US2023080536A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.